Coronary heart disease risk assessment in diabetes mellitus - A comparison of PROCAM and Framingham risk assessment functions

Diabetic Medicine

Volumn 18, Issue 5, 2001, Pages 355-359

  Game, F L ^a   Jones, A F ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Coronary heart disease; Diabetes mellitus; Framingham; PROCAM; Risk

Indexed keywords

TRIACYLGLYCEROL;

ADULT; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 0034916567     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2001.00438.x     Document Type: Article

References (18)

1. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
2. Randomised controlled trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
5. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
6. Joint British recommendations on prevention of coronary heart disease in clinical practice
7. Cardiovascular disease risk profiles
8. Diabetes and cardiovascular risk factors: The Framingham Study
9. Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic
10. Statistical methods for assessing agreement between two methods of clinical measurement
11. Section 31. The results of the Framingham study applied to four other US-based epidemiological studies of cardiovascular disease
12. Baseline risk factors and their association with outcome in the West of Scotland coronary prevention study
13. Using the Framingham model to predict heart disease in the United Kingdom: Retrospective study
14. CHD risk equations, obtained from the Framingham Heart Study, applied to PROCAM Study
15. Diabetes-mellitus
16. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men